Intragastric Balloon Market Size & Share, Balloon Type (Single, Dual, Triple); Filling Material; Administration; End use - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

Intragastric Balloon Industry - Regional Synopsis

North America Market Statistics   

North America intragastric balloon market is expected to capture revenue share of over 41.3% by 2037, driven by its high rate of obesity, thereby providing an enormous and easily accessible pool of patients. This common clinical requirement, combined with the region's highly advanced medical infrastructure and well-established reimbursement streams, enables rapid take-up and dissemination of intragastric balloon treatments. Thus, sheer numbers of prospective patients stimulates the surging demand for market.

The U.S. market is growing exponentially owing to the smooth approvals and conducive regulatory ecosystem that push innovation & breakthroughs in gastric balloon techniques.  For instance, in April 2022, it was revealed that the FDA authorized the Spatz3, the first adjustable intragastric balloon (aIGB) on the market in the United States, in October 2021. For individuals with obesity who have not been able to lose weight and keep it off with a supervised weight control program, it is recommended for short-term use (up to eight months).

Canada market is likely to witness substantial growth during the forecast period driven by its universal health policy, offering comparatively extended access to weight reduction interventions, such as intragastric balloons, when medically necessary. For instance, in November 2024, Novo Nordisk's new weight-loss medication, Wegovy has been licensed by Canada's health regulator to lower the risk of myocardial infarction or nonfatal heart attack in adults. It was the first medication authorized in Canada to treat adults with existing cardiovascular disease who are obese and at risk for heart-related diseases.

Asia Pacific Market Analysis

The intragastric balloon market in Asia Pacific is gaining traction and is expected to witness lucrative growth during the forecast timeline. The region offers a fast-growing environment in the market, mainly because of the middle-class growth and the subsequent increase in lifestyle diseases, with obesity and metabolic syndrome at the forefront. This demographic change, combined with greater access to sophisticated medical equipment and greater awareness of minimally invasive weight loss procedures, presents a huge and growing patient base.

India increasing market is being driven foremost by the rapidly expanding urban population of the nation and the parallel rise in sedentary living, thereby recording a fast boost in obesity as well as connected comorbidities. For instance, in March 2025, according to data from the National Family Health Survey (NFHS)-5 (2019–21), 24% of Indian women and 23% of Indian men are overweight or obese. 6.4% of women and 4.0% of men in the 15–49 age group are obese, according to the NFHS-5 (2019–2021). Additionally, the proportion of children under five who are overweight (weight-for-height) has increased from 2.1 percent in NFHS-4 (2015–16) to 3.4 percent in NFHS-5 (2019–21) at the All-India level.

China intragastric balloon market is witnessing lucrative growth opportunities owing to its robust technological-driven ecosystem, which fosters evolution in technologies and methodologies for treatments. For instance, in February 2025, the launch of the high-end precision minimally invasive surgical tools production expansion project was launched in Zibo City. Xinhua Surgical Instruments Co., Ltd., announced with pride an anticipation of more than 4.7 million pieces of open surgical instruments and 19,000 sets of minimally invasive laparoscopic surgical instruments to be produced annually. This represents a significant increase in production capacity and will firmly establish the company's position in the market.